REFERENCES
- Aungst B. J., Rogers N. J., Shegter E. Enhancement of naloxone penetration through human skin in vitro using fatty acids, fatty alcohols, surfactants, sulfoxides and amides. Int. J. Pharm. 1986; 33: 225–234
- Chien Y. W., Lau E. P. K. Controlled drug release from polymeric delivery devices IV: In vitro-in vivo correlation of subcutaneous release of norgestomet from hydrophilic implants. J. Pharm. Sci. 1976; 65: 488–492
- Coutel-Egros A., Maitani Y., Veillard M., Machida Y., Nagai T. Combined effects of pH cosolvent and penetration enhancers on the in vitro buccal absorption of propanolol through excised hamster cheek pouch. Int. J. Pharm. 1992; 84(117)128
- Dariusz N. D., Antczak A., Król M. Antioxidant properties of ambroxol. Free Radical Biology and Medicine 1994; 16: 517–522
- Diaz J. P., Manresa P. F., Benasco C., Guardioia J., Munoz L., Clariana A. Response to surfactant activator (ambroxol) in alveolar proteinosis. Lancet 1984; 1(8384)1023
- Durrhein H., Flynn G. L., Higuchi W. I., Behl C. R. Permeation of hairless mouse skin I: experimental methods and comparison with human epidermis permeation by alkanols. J. Pharm. Sci. 1980; 69: 781–786
- Ericsson C. H., Juhasz J., Johnson E., Mossberg B. Ambroxol and simple chronic bronchitis: Effects on subjective symptoms and ventillatory function. Respiration 1987; 51(Suppl 1)33–36
- Guyatt G. H., Townsend M., Kazim F., Newhouse M. T. A controlled trial of ambroxol in chronic bronchitis. Chest 1987; 92: 618–620
- Ishida M., Machida Y., Nambu N., Nakai T. New mucosal dosage form of insulin. Chem. Pharm. Bull. 1981; 209: 810–816
- Kartz M., Polsen B. Absorption of drugs through the skin. Handbook of Experimental Pharmacology, B. B. Brodie, J. R. Gillette. Springer, New York 1971; 103–174
- Miyazaki S., Takeuchi S., Yokouchi C., Takada M. Pluronic F-127 gels as a vehicle for topical administration of anticancer agents. Chem. Pharm. Bull. 1984; 32(–)4205–4208
- Olivieri D., Zavattini G., Tomasini G., Daniotti S., Bonsignore G., Ferrara G., Carnimeo N., Vhianese R., Catena E., Marcatili S. Ambroxol for the prevention of chronic bronchitis exacerbations: Long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: A double-blind study versus placebo. Respiration 1987; 51: 42–51
- Ratjen F., Wonne R., Posselt H. G., Stover B., Hofmann D., Bender S. W. A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. Eur. J. Pediatr. 1985; 144: 374–378
- Severina I. S., Bussygina O. G., Pyatakova N. V., Khropov Y. V., Krasnoperov R. A. Ambroxol as an inhibitor of nitric oxide-dependent activation of soluble guanylate cyclase. Eur. J. Pharmacology 2000; 407: 61–64
- Shin S. C., Kim J. Y. Enhanced permeation of triamcinolone acetonide through the buccal mucosa. Eur. J. Pharm. Biopharm. 2000; 50: 217–220
- Shin S. C., Kim J., Yoon M. K., Oh I. J., Choi J. S. Transdermal delivery of triprolidine using TPX polymer membrane. Int. J. Pharm. 2002; 235: 141–147
- Vanlommel N. S., Verbeken E. K., Lauweryns J. K., Demedts M. Lung injury induced by paraquat, hyperoxia and cobalt chloride: Effects of ambroxol. Pulm. Pharmacol. 1992; 5: 53–60
- Vergin H., Bishop-Freundling G. B., Micka M., Nitsche V., Strobel K., Matzkies F. Untersuchungen zur pharmakokinetik und bioaquivalenz unterschiedlicher darreichungsformen von ambroxol. Arzneim-Forsch./Drug Res. 1985; 35: 1591–1595